文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

定制双倍剂量自适应加速分期放射外科治疗预后受限的危重部位脑转移瘤:长期回顾性分析

Management of critically located brain metastases in patients with precluded survival using customised double-dose prescription-based, adaptive accelerated staged radiosurgery: a long-term retrospective analysis.
PubMed 文献 · Radiat Oncol · 2025-08-01

这项回顾性可行性研究分析了29例共35个脑转移瘤患者,因不适合手术、放疗或系统治疗而接受MRI引导的自适应伽玛刀放射外科,分3次、间隔72小时,每次采用定制同步双倍剂量处方。中位总生存7.3个月,1年局部肿瘤控制率75%,全程无神经性死亡,5例出现放射不良反应其中4例无症状。

要点

  • 定制双倍剂量自适应加速放射外科可达到可接受的局部肿瘤控制和放射不良反应率。
  • 中位总生存7.3个月,1年局部肿瘤控制率75%,全程避免神经性死亡。
  • 5例出现放射不良反应,其中4例全程无症状。

核心结论

  • 定制双倍剂量自适应放射外科在极差预后脑转移瘤患者中提供了可接受的局部肿瘤控制和放射不良反应率,并全程避免神经性死亡。

研究设计与样本

  • 回顾性可行性研究纳入29例患者共35个脑转移瘤,均被判定不适合手术、放疗或系统治疗。
  • 治疗采用MRI引导的自适应伽玛刀放射外科,分3次独立Session、间隔72小时,每次系统采用定制同步双倍剂量处方。
  • 治疗前因靶颅内病灶估计生存不足4周,随访7.5年,重点分析生存≥12个月者。

主要发现

  • 中位总生存7.3个月,6、12、24、36、48和60个月生存率分别为62%、41%、17%、14%、10%和7%。
  • 1年局部肿瘤控制率为75%。
  • 4例在随访后期出现局部复发,生存时间12至40个月。
  • 投稿时2例存活(治疗后115和117个月)且无后遗症,其余死于全身疾病进展,全程无神经性死亡。
  • 5例报告放射不良反应,其中4例全程无症状。

临床怎么用

  • 对于因病灶危重部位而不适合手术、放疗或系统治疗的脑转移瘤患者,可考虑定制双倍剂量自适应加速分期放射外科作为可行选择。
  • 治疗中需系统采用同步双倍剂量处方并分次间隔72小时实施,同时密切监测放射不良反应。

局限性

  • 本研究为回顾性可行性研究,样本量小(29例患者35个病灶),需更大样本、同质组织学的前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with brain metastases face a poor prognosis when deemed not to be suitable for onco-surgical intervention. This feasibility study analyses the outcome of adaptive radiosurgery applied in customised settings to a group of patients with brain metastases, where no other form of treatment was deemed safe and/or feasible. METHODS: 29 patients with 35 brain metastases deemed not to be candidates for surgery, radiotherapy or systemic treatment were treated with MRI-guided adaptive Gamma Knife radiosurgery in 3 separate sessions with a 72-hour interval. Customised synchronous double-dose prescriptions were systematically utilised at each session. Estimated survival at pre-treatment was fewer than 4 weeks due to the targeted intracranial lesions. A retrospective analysis was conducted on the whole cohort, with particular emphasis on those surviving 12 months and beyond. RESULTS: The median overall survival was 7.3 months, with a follow-up of 7.5 years. Survival at 6, 12, 24, 36, 48 and 60 months was 62%, 41%, 17%, 14%, 10% and 7%, respectively. Local tumour control (LTC) at 1 year was 75%. 4 patients developed local recurrence late on follow-up, with a survival ranging between 12 and 40 months. 2 patients were alive at the time of submission (115- and 117-months post-treatment) with no sequelae; the remainder succumbed to general disease progression, with neurologic death being avoided throughout the whole cohort. Adverse radiation effects (ARE) were reported in 5 patients, of which 4 remained asymptomatic throughout follow-up. CONCLUSIONS: Based on the results of this first retrospective study, adaptive radiosurgery in double-dose prescription settings provided acceptable rates of LTC and ARE despite the underlying accelerated timeline, ultimately preventing neurologic death in a group of patients with an extremely poor prognosis. Prospective studies involving a larger number of patients with homogenous histology are warranted to validate the results of this study and optimise the technique.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sinclair G, Martin H, Allison CM, et al. Management of critically located brain metastases in patients with precluded survival using customised double-dose prescription-based, adaptive accelerated staged radiosurgery: a long-term retrospective analysis. Radiat Oncol. 2025. PMID: 40750901. doi:10.1186/s13014-025-02692-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。